AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019 - ResearchAndMarkets.com

May 6, 2019

DUBLIN--(BUSINESS WIRE)--May 6, 2019--The “5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and the remaining by universities/institutes. This report outlays comprehensive information on the 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5′ nucleotides. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

This report also reviews key players involved in 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
  • The report reviews 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

  • Arcus Biosciences Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • Corvus Pharmaceuticals Inc
  • Evotec AG
  • I-Mab Biopharma Co Ltd
  • Innate Pharma SA
  • InteRNA Technologies BV
  • MedImmune LLC
  • Novartis AG
  • Oric Pharmaceuticals Inc
  • Peloton Therapeutics Inc
  • Selvita SA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w7r0cv

View source version on businesswire.com:https://www.businesswire.com/news/home/20190506005320/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/06/2019 05:56 AM/DISC: 05/06/2019 05:56 AM

http://www.businesswire.com/news/home/20190506005320/en